---
title: Validation of the Revised 2022 European LeukemiaNet Risk Stratification in
  Adult Patients with Acute Myeloid Leukemia
date: '2024-11-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39504561/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241106184430&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: In 2022, the European LeukemiaNet (ELN) risk stratification for patients
  with AML has been updated. We aimed to validate the prognostic value of the 2022
  ELN classification (ELN22) evaluating 1,570 newly diagnosed AML patients (median
  age, 56 years) treated with cytarabine-based intensive chemotherapy regimens. As
  compared to the 2017 ELN classification (ELN17), allocating 595 (38%), 413 (26%)
  and 562 (36%) patients to the favorable, intermediate and adverse risk category,
  ELN22 risk ...
disable_comments: true
---
In 2022, the European LeukemiaNet (ELN) risk stratification for patients with AML has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) evaluating 1,570 newly diagnosed AML patients (median age, 56 years) treated with cytarabine-based intensive chemotherapy regimens. As compared to the 2017 ELN classification (ELN17), allocating 595 (38%), 413 (26%) and 562 (36%) patients to the favorable, intermediate and adverse risk category, ELN22 risk ...